Latest Updates
-
The Mental Health Side Of Breastfeeding No One Really Talks About: What An Expert Wants You To Know -
Who Is Shreya Kalra? Meet The Lock Upp Season 2 Winner Who Took Home ₹1 Crore, Beating Shivangi Joshi -
Chandipura Virus Outbreak In Gujarat: 22 Children Dead; Expert Explains Symptoms, Prevention And Treatment -
Who Is Mini Mathur? Meet The Alliance Winner Who Beat Aly Goni To Win ₹50 Lakh Cash Prize -
Throwback Thursday: 6 Reasons 'Jaane Tu... Ya Jaane Na' Was Secretly Gen Z Before Gen Z Existed -
Hiroshima Day: Five Medical Discoveries That Emerged From One of History's Greatest Tragedies -
Why Young Adults Ignore Persistent Swelling for Months — And When It May Be Sarcoma -
Bigg Boss 20 Premiere Date Out: Salman Khan's Karan Arjun Tease Sparks SRK Buzz -
India's 101st Ramsar Site: What's Special About Arunachal Pradesh's Glaw Lake -
Gujarat's Chandipura Virus Outbreak: 22 Children Dead, Here's What Parents Must Know
Corbevax Will Be Allowed As A Booster For Those Fully Vaccinated With Covishield Or Covaxin
Allowing Biological E's Corbevax as a booster for those fully vaccinated against COVID-19 with either Covishield or Covaxin is likely to be considered by the NTAGI, which is scheduled to meet on Tuesday, sources said.

The Drugs Controller General of India (DCGI) on June 4 approved Corbevax as a precaution dose for those aged 18 and above. India's first indigenously-developed RBD protein subunit vaccine, Corbevax, is currently being used to inoculate children in the age group of 12 to 14 years.
"The National Technical Advisory Group on Immunisation (NTAGI) will discuss allowing Corbevax, which has been cleared by the DCGI, as a booster for those fully vaccinated with Covishield or Covaxin," a source told PTI.
The government advisory panel is also expected to review the trial data of the country's first quadrivalent human papillomavirus (qHPV) vaccine against cervical cancer, developed by the Serum Institute of India.
A separate HPV working group of the NTAGI had, on June 8, examined the vaccine's clinical trial data and usefulness for inclusion in the national immunisation programme, sources had said.
The recommendation of the Standing Technical Sub-Committee (STSC) of the NTAGI on reducing the gap between the second dose and the precaution dose of Covid vaccines from nine to six months may also be ratified at the meeting to be chaired by the Union health secretary. PTI PLB RC
Disclaimer: The information provided in this article is for general informational and educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or a qualified healthcare provider with any questions you may have regarding a medical condition.



Click it and Unblock the Notifications